Senate Begins Investigation Into Ozempic and Wegovy Prices [The New York Times]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: The New York Times
A Senate committee is investigating the prices that Novo Nordisk charges for its blockbuster medications, Ozempic and Wegovy, which are highly effective at treating diabetes and obesity but carry steep price tags.Senator Bernie Sanders of Vermont, the chair of the Senate Committee on Health, Education, Labor and Pensions, said in an interview that the prices must “be lowered in order for consumers to get it, and for governments not to go bankrupt providing it.” The list price of Ozempic, which is authorized for Type 2 diabetes, is around $968 per package. Wegovy, which is approved for weight loss and toreduce the risk of heart problemsIn a letter sent Wednesday to Lars Fruergaard Jorgensen, Novo Nordisk’s chief executive, Mr. Sanders wrote that the committee was requesting internal communications on the prices of these drugs in the United States, which is higher than the cost in other countries. The committee also requested information on why the company charges more for Wegovy when t
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Why Amgen Stock Zoomed Nearly 12% Higher Today [Yahoo! Finance]Yahoo! Finance
- Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market [Yahoo! Finance Canada]Yahoo! Finance Canada
- Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market [Yahoo! Finance]Yahoo! Finance
- The two ways Amgen's new weight-loss drug can stand out [Yahoo! Finance]Yahoo! Finance
- The two ways Amgen's new weight-loss drug can stand out [Yahoo! Finance Canada]Yahoo! Finance Canada
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 5/2/24 - Form 6-K
- 5/1/24 - Form 6-K
- 4/26/24 - Form 6-K
- NVO's page on the SEC website